Eaton Vance Ltd Duration Income Fund
Change company Symbol lookup
Select an option...
XEVVX Eaton Vance Ltd Duration Income Fund
JNJ Johnson & Johnson
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
Go

Company profile

Eaton Vance Limited Duration Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide a high level of current income. The Fund may, as a secondary objective, also seek capital appreciation to the extent it is consistent with its primary objective. The Fund may invest in Eaton Vance Cash Reserves Fund, LLC (Cash Reserves Fund). The Fund invests in various sectors, including aerospace and defense, air transport, automotive, beverage and tobacco, brokerage/securities dealers/investment houses, building and development, cable and satellite television, chemicals and plastics, electronics/electrical, financial intermediaries, food products, equipment leasing, lodging and casinos, oil and gas, industrial equipment, home furnishings, leisure goods/activities/movies, healthcare, telecommunications, publishing and insurance, among others. The Fund's investment advisor is Eaton Vance Management (EVM).

Closing Price
$13.48
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STAA, AYX and MESO

2:25 pm ET October 14, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 14, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Staar Surgical Company (NASDAQ:STAA)

Investors Affected: February 26, 2020 - August 10, 2020

A class action has commenced on behalf of certain shareholders in Staar Surgical Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company was overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/staar-surgical-company-loss-submission-form/?id=10125&from=1

Alteryx, Inc. (NYSE:AYX)

Investors Affected: May 6, 2020 - August 7, 2020

A class action has commenced on behalf of certain shareholders in Alteryx, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was unable to close large deals within the quarter, and deals were pushed out to subsequent quarters or downsized; (2) as a result, Alteryx increasingly relied on adoption licenses to attract new customers; (3) as a result and due to the nature of adoption licenses, the Company's revenue was reasonably likely to decline; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/alteryx-inc-loss-submission-form/?id=10125&from=1

Mesoblast Limited (NASDAQ:MESO)

Investors Affected: April 16, 2019 - October 1, 2020

A class action has commenced on behalf of certain shareholders in Mesoblast Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/mesoblast-limited-loss-submission-form/?id=10125&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (212) 537-9430Fax: (833) 862-7770

SOURCE: The Gross Law Firm

View source version on accesswire.com: https://www.accesswire.com/610500/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-STAA-AYX-and-MESO

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.